US Blog re Court Case(s)14 Nov 2018 11:51
Interesting article written in seeking alpha last month. Nothing new regards to the court cases Silence has with Alnylam, but interesting comments from the blogger re the Netherlands. As we know Silence has filed suits in the UK, Portugal and the Netherlands with the UK case to start in December.
For the last year since I have been watching Silence, I have always found it strange that US commentators or Equity Analysts on Alnylam's quarterly calls had not mentioned the court cases. I guess it isn't strange that the equity analysts don't mention it as they still suffer from positive bias and want to be on the next quarterly calls. However, this is the first time I personally have seen a US commentator mention the cases. This can only be a good thing for those, myself included, who want Silence to be taken over.
I have also included the recent comments from David Horn CEO, relating to the filing in the Netherlands.
https://seekingalpha.com/instablog/38002746-denniskneale/5229047-clash-dark-dna-pioneers.
"The third case, however, in the Netherlands, may be the most serious threat against Alnylam. The first two filings are patent-infringement actions, and if Silence wins, Alnylam can keep appealing and delaying. By contrast, Silence filed its third action in the Netherlands (where Alnylam’s Dutch subsidiary holds the Onpattro authorization) for a different Silence patent, EP 3 222 724, and under Dutch case-law, which allows patentees to stop Dutch companies from patent infringement, rather than a pure-bred patent-infringement case. Injunctions granted in such cases are effective in every European country where the Silence patent exists. Thus, it could result in a total ban on sales of the new drug across all of Europe where Silence has patent rights.
That would be a staggering blow to Alnylam’s business. Its first and only approved drug, Onpattro is likely to account for 44% of total revenue in 2023, according to Cowen Research; at Morgan Stanley, the estimate is an overwhelming 75% of sales in 2023. Think about the bet that ALNY is making right now: It risks losing the lifeblood of its business for refusing to pay a rival a pittance in patent fees."
https://www.proactiveinvestors.co.uk/companies/news/206742/silence-therapeutics-s-alnylam-wrangle-takes-a-new-turn-206742.html
Chief executive David Horn Solomon said: "Silence continues to innovate with new, competitive RNAi medicines.
“During 2017 and 2018, the European Patent Office has upheld the validity of our expanding patent estate with the granting of additional patents around our foundational chemical modification IP.
“When companies openly promote new product commercialisation in the face of relevant granted patent rights, Silence Therapeutics will take steps to enforce its patents and protect the historic investment made in its technology."
Sign In
Follow the stocks
